909 Fannin Street
OncoResponse, a privately held immuno-oncology company, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to the discovery of cancer therapeutics.
OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of antibody-derived therapeutics for the treatment of cancer, thereby extending the benefit of immunotherapy to a greater number of patients.
CEO: Clifford J. Stocks
CSO: Kristine Swiderek, Ph.D.
CFO: Russ Hawkinson
Please click here for OncoResponse's technology.
8 articles with OncoResponse
April springs up with showers of cash for these life sciences companies.
- New capital will fund lead antibody, OR2805, through Phase 1 and 2 clinical studies - Adds Magnetar Group, Yonjin Ventures and Bering Capital to the syndicate
Adds RiverVest Venture Partners, Qatar Investment Authority and Redmile Group to List of Financial Backers
OncoResponse Expands Scientific Leadership With the Addition of Dr. Anil Singhal as CSO and Dr. Kamal D. Puri as VP, R&D
OncoResponse today announced it has expanded its scientific leadership through the additions of Anil Singhal, Ph.D., and Kamal D. Puri, Ph.D., to the management team.
OncoResponse today announced that it has closed the acquisition of Paganini Biopharma, acquiring all of its assets including an anti-epithelial membrane protein 2 (EMP2) fully human monoclonal antibody, ONCR-201.